

INFECTIVE ENDOCARDITIS AND DENTISTRY

SHAH S FAYYAZ AHMED, MRCP (UK)

ABSTRACT

Infective endocarditis is the infection of endothelium of heart and vessels. It is an uncommon condition associated with substantial mortality and morbidity. It is a common belief that it could possibly be prevented by appropriate use of antibiotic prophylaxis. The objective of this review is to provide the background knowledge of infective endocarditis in terms of etiology, pathogenesis, clinical features, diagnostic strategies and preventive aspects. The extensive search of Medline from 1986 to January 2007 was performed. There were almost 100 articles which were relevant to the subject and were chosen to extract the possible information.

There has been considerable controversy in the past as to what sort of dental procedures are to be blamed and which group of patients should receive prophylactic antibiotics. The guidelines have frequently been revised and two main guidelines namely of American Heart Association (AHA) and of British Society of Antimicrobial Chemotherapy (BSAC) are currently being practiced. For a dentist these guidelines are often confusing and cumbersome. This article is aimed at relieving the undue anxiety of a dentist when he comes across with a patient predisposed to infective endocarditis and to create a better understanding between dentist, patient and cardiologist.

Key words: *Endocarditis, Dental Procedures, Prophylaxis*

INTRODUCTION

Infective Endocarditis is a microbial infection of endothelial surface of the heart. The characteristic lesion is vegetation, which is a mass of fibrin, platelets and microorganisms embedded inside. Heart valves are the most common sites of involvement beside septal defects, chordae tendinea and mural endocardium. Infection can also occur at arteriovenous Shunts whether congenital or acquired, arterio-arterial Shunts like Patent ductus arteriosus or co-arcuation of aorta. Many species of bacteria, fungi, mycobacteria, mycoplasma, Rickettsia, and Chlamydia can cause infective endocarditis (IE) but majority of the cases are due to streptococci, staphylococci, enterococci, and gram negative coccobacilli^{1-2,3}.

Oftenly we use the terms acute and sub-acute infective endocarditis. Acute IE is a serious disease with marked toxicity, destruction of valves and meta

static infection while sub-acute IE progresses over weeks and months. Acute infections are usually caused by Staphylococcus Aureus whereas sub-acute by Streptococcus viridians, Enterococcus and Gram-negative Coccobacillus. In recent years Staphylococcus has been shown to surpass Streptococcus viridians as the most common cause of infective endocarditis, the reason being the recent deterioration of anti-biotics susceptibility among the group of gram —positive cocci⁴⁻⁶.

The incidence of IE remains relatively stable from 1950 through 1987 to 1999, at about 4.2 to 5.9 per 100,000 patients year¹. Higher incidence of 11.6 episode per 100,000 patients has been reported from Sweden¹. Endocarditis usually occurs more frequently in men. Gender derived ratios range from 1.6 to 2.5 (women vs. men). The age specific incidence of endocarditis increases progressively over 30 years of age and exceeds 14.5 to 30 case per 100,000 persons year³.

The pre-disposing conditions like Congenital Heart Disease, Rheumatic Heart Disease, Mitral Valve Prolapse, Degenerative Heart Disease, Asymmetrical Septal Hypertrophy or Intravenous drug abuse is present in about 35-75 % of the cases². Majority of the rest of the cases are due to involvement of prosthetic valves. Predisposing conditions remain unidentified in some patients²⁻³. The incidence of IE in children ranges from 1 in 4500 to 1 in 1280. These children usually have underlying Congenital Heart Disease.^{1,2,3}

In adults, Mitral Valve Prolapse has emerged as a major predisposing structural cardiac abnormality accounting for 7 to 30 % of native valve endocarditis^{12,13}. Rheumatic Heart Disease is the next common condition, accounting for 20-25 % of the cases reported in 1970 and now more recently reported from North America and Europe the RHD predisposed to IE in only 7 and 18% of the cases². Usually the Mitral Valve is involved, more so in women followed by Aortic Valve, which is more commonly involved in men. In under developed part of the world, Rheumatic heart disease is still the most commonly found underlying cardiac abnormality and presents at early age². In developed countries the incidence of Rheumatic heart disease has decreased however the incidence of endocarditis remains the same as the spectrum of underlying heart disease has changed. Congenital Heart Disease is responsible for 10-20 % of the cases. The most common lesions are Patent Ductus Arteriosus, Ventricular Septal Defect and Bicuspid Aortic Valve.

The risk of IE in drug abuser is 2-5 % patient years. The most common cases are recognized in men, age ranges from 27-37 years,⁷⁻¹⁰. The most common site involved is the Tricuspid Valve (46-78%) followed by Mitral and Aortic Valve. In 75-93 % of the cases of IE in intravenous drug abusers valves were normal, before IE and the remaining patient had preexisting Mitral or Aortic disease. Fifty percent of the cases of IE in I.V. drug abuser are due to staphylococcus, but other organisms particularly unusual microorganisms like *Corynebacterium*, *Lactobacillus* and *Nisseria* species have been identified in about 3-5 % of the case¹⁰

Prosthetic valve endocarditis accounts for 7 — 25% of the cases of infective endocarditis. In most developed countries, during the first three months post replace-

ment, the mechanical valves are at higher risk than bioprosthesis but later the risk of IE becomes same for both types^{11,14,15,16}. Cases with onset within 2 months after surgery are called early onset prosthetic valve endocarditis and are acquired in hospital. Cases occurring 12 months after surgery are called late prosthetic valve endocarditis and are community acquired. Cases between two and twelve months after surgery are mixed either hospital acquired or caused by less virulent microorganisms acquired from community. Late-onset prosthetic valve endocarditis is more frequent now because patients with prosthetic heart valves are surviving longer. Fortunately, these cases are caused by the same organisms as native valve endocarditis (NVE), and are usually easier to treat¹⁴⁻¹⁶.

The HACEK group of fastidious gram-negative bacteria can cause endocarditis. HACEK is term used for endocarditis due to *Haemophilus*, *Actinobacillus*, *Cardio bacterium*, *Eikenella*, and *Kingella* species of bacteria. Clinically, these cases are characterized by a sub acute course, and often present with embolic lesions from large vegetations".

Most cases of fungal endocarditis occur in patients who are receiving prolonged antibiotics or parenteral nutrition through central vascular catheters. Such patients may also be immunocompromised. The most common species is *Candida albicans*, followed by *Candida parapsilosis*. Endocarditis due to *Histoplasma capsulatum* or *Aspergillus* species is rare^{18,19}.

Unusual cases of endocarditis should be considered when standard microbiologic techniques fail to provide a diagnosis. Q-fever endocarditis due to *Coxiellaburnetii* is an example. Patients may not have fever, but they frequently have underlying valvular heart disease and are on immuno-suppressive therapy. *Bartonella henselae* may also cause endocarditis, and diagnosis here is also difficult. Such infections are seen in the homeless and alcoholic population²⁰ Non bacterial thrombotic endocarditis may be caused by endothelial injury and hypercoagulable state. It is more common with advancing age and in patients with malignancy, chronic renal failure, SLE, intracardiac catheters and valvular heart disease. Bacteraemia associated with health care procedures converts nonbacterial thrombotic endocarditis (NBTE) to infective endocarditis (IE)²¹.

The interval between presumed bacteraemia and the onset of symptoms of IE is less than two weeks²². Fever may be absent in elderly patients. Heart murmurs are audible in 80 % of the patient. New murmurs or changing murmurs are usually found in acute IE²³⁻²⁸. Spleen is enlarged in 15-50 % of the patients²². Certain peripheral manifestations of IE, Petechiae, Splinter or Sub-ungual Hemorrhage, Osler's node, Janeway lesion and Roth spots are not that common²⁹. The muscular symptoms like myalgias, arthralgias are quite common. Systemic embolisation is a serious complication and often found the cause of death at autopsy, Coronary, Cerebral, Renal and the Peripheral arteries maybe involved²⁹⁻³².

Von Reyn and associates³³ suggested the criteria for the diagnosis of endocarditis (Table 1). A positive valve culture or histology was the basis for the diagnosis of IE. Major criteria for probable endocarditis were either persistent bacteraemia with a new regurgitant heart murmur or valvular heart disease with vasculitis; or negative or intermittent bacteraemia with fever and a new regurgitant heart murmur with vasculitis.

TABLE 1: MODIFIED FROM REFERENCE 33

Von Reyn Criteria for the Diagnosis of Infective Endocarditis	
<input type="checkbox"/>	Positive valve culture or histology or
<input type="checkbox"/>	Persistent bacteraemia with new regurgitant heart murmur or valvular heart disease and vasculitis or
<input type="checkbox"/>	Negative or intermittent bacteraemia and fever; plus new Regurgitant heart murmur and vasculitis

Diagnosis of IE nowadays is based on the presence of either major or minor clinical criteria according to modified Duke Criteria³⁴. Major criteria in the Duke strategy included IE documented by data obtained at the time of open heart surgery or autopsy (pathologically definite) or by well-defined microbiological criteria (high-grade bacteraemia or fungemia) plus echocardiographic data (clinically definite). Duke criteria gave diagnostic weight to bacteraemia with staphylococci or enterococci only when they were community acquired and without an apparent primary focus; these latter types of bacteraemia have the highest risk of being associated with IE.

The Duke criteria incorporated echocardiographic findings in the diagnostic strategy. Major diagnostic weight was given to only 3 typical echocardiographic findings: mobile, echo dense masses attached to valvular leaflets or mural endocardium; periannular abscesses; or new dehiscence of a valvular prosthesis.

Six common but less specific findings of IE also were included as minor criteria in the original Duke schema; intermittent bacteraemia or fungemia, fever, or major embolic events, nonembolic vascular phenomena, underlying disease or injection drug use, and echocardiographic abnormalities that fell short of typical valvular vegetations abscesses, or dehiscence. Clinically definite IE by the Duke criteria required the presence of 2 major criteria, 1 major criterion and 3 minor criteria, or 5 minor criteria.

Severe refinements have been made recently to both the major and minor Duke criteria³⁴⁻³⁸. As noted above, in the original Duke criteria, bacteraemicriteria³⁴⁻³⁶ from *S aureus* was considered to fulfill a major criterion only if it was community acquired because ample literature has suggested that this parameter is an important surrogate marker for underlying IE. An increasing number of contemporary studies, however, have documented IE in patients experiencing nosocomial staphylococcal bacteraemia³⁷.

Therefore, the modified Duke Criteria (Tables 2A and 2B) recommend the inclusion of *S aureus* bacteraemia as a major criterion, regardless of whether the infection is nosocomially acquired (with or without a removable source of infection) or community acquired.

Lab tests show abnormal hematological parameters. Normochronic normocytic anemia, Low Serum Iron Level, Leukocytosis, elevated ESR is commonly found. Anemia worsens with increasing duration of illness and it may be absent in acute IE. White cell count may be normal in sub acute IE and presence of leukocytosis points towards acute **IE**. Circulating Immune Complexes, Rheumatoid factor, and C-reactive proteins are often positive and their presence correlates with disease activity. Proteinuria and Hematuria is most commonly encountered abnormality while performing urine analysis of such patients³⁸.

Echocardiography remains the gold standard diagnostic tool of the diagnosis of IE. Many patients can be

TABLE 2A: MODIFIED FROM REFERENCE 34

Definite Infective Endocarditis			
Pathological Criteria	Clinical Criteria	Possible IE	Rejected
Microorganisms demonstrated by culture or histological examination of a vegetation, a vegetation that has embolized, or an intracardiac abscess specimen	2 major criteria; or 1 major criterion and 3 minor criteria; or 5 minor criteria	1 major criterion and 1 minor criterion; or 3 minor criteria	Firm alternative diagnosis explaining evidence of IE; or Resolution of IE syndrome with antibiotic therapy for < 4 days; or No pathological evidence of IE at surgery or autopsy; with antibiotic therapy for < 4 days; or Does not meet criteria for possible IE as above

TABLE 2B: MODIFIED FROM REFERENCE 34

Definition of Terms Used in the Modified Duke Criteria for the Diagnosis of Infective Endocarditis		
Major Criteria		Minor Criteria
Blood Culture for positive IE	Evidence of endocardial involvement	Predisposition, predisposing heart condition, or IDU Fever temperature > 38 ° C Vascular phenomena, major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway's lesions Immunologic Phenomena: glomerulonephritis, Osler's nodes, roth's spots, and rheumatoid factor Microbiological evidence: positive blood culture does not meet a major criterion as above or serological evidence of active infection with organism consistent with IE
Typical microorganisms consistent with IE from 2 separate blood cultures; Viridians streptococci, <i>Streptococcus bovis</i> , HACEK group, <i>Staphylococcus aureus</i> ; or community-acquired enterococci in the absence of a primary focus;	Echocardiogram positive for IE (TEE recommended for patients with prosthetic valves, rated at least "possible IE" by clinical criteria, or complicated IE [paravalvular abscess]; TTE as first test in other patients) defined as follows: oscillating intra cardiac mass on valve or supporting structures, in the path of regurgitant jets, or on Implanted material abscess; or new partial dehiscence of prosthetic valve; new valvular regurgitation (worsening or changing or preexisting murmur not sufficient	
or Microorganisms consistent with IE from persistently positive blood cultures defined as follows: At least 2 positive cultures of blood samples drawn > 12 h apart; or all 3 majority of > 4 separate cultures of blood (with first and last sample drawn at least 1 h apart) Single positive blood culture for <i>Coxiella burnetti</i> or anti-phase 1 IgG Antibody titer > 1:800		

imaged adequately by Trans Thoracic Echo. However, TEE (Trans Esophageal Echo) has invariably been required in patients who have strong clinical suspicion of IE^{36,39}. The establishment of microbial cause is of utmost importance. Infection is recovered from blood

or from the surgically removed vegetation. Three separate sets of blood Cultures are required within 24 hours, obtained via separate venepunctures. Laboratory should be instructed to look for atypical microorganisms also.

The clinical features of infective endocarditis result from the local destructive effects of intracardiac lesions, septic embolisation, hematogenous spread leading to persistent bacteraemia and deposition of immune complexes.

Dental Procedures as risk factor

Bacteraemia commonly occurs during activities of daily living such as tooth brushing or food chewing. Significant bacteraemias caused by organisms commonly associated with IE are attributable to specific procedures⁴⁶⁻⁴⁶. Genesis of bacteraemia generally is considered when a dental procedure leads to bleeding^{44,45}. Complete denture prostheses for edentulous mouth do not pose risk of IE. Decreased risk was suggested by use of dental floss once a day⁴⁷.

There is overwhelming evidence that bacteraemia result from oral/dental surgical and non-surgical treatment. However, the risk of **IE** due to this bacteraemia is still debated.⁴⁸⁻⁵¹ Risk of IE increases in individual with poor periodontal health or other oral infections (52-56). Rinsing with Chlorhexidine Gluconate or Povidone-Iodine is recommended prior to manipulation of Dental tissue. To date, there is no conclusive evidence that confirms the reduction of bacteraemia by oral bio load⁵⁷⁻⁶⁵.

Any bacteraemia occurring during dental treatment does not significantly increase the risk of Endocarditis⁶⁶. A recent Cochrane review⁶⁷ concluded that

there was no evidence to support the use of prophylactic penicillin to prevent endocarditis in invasive dental procedures. The working party however, agreed that ideally a prospective double blind trial to evaluate the risk/benefit of prophylactic antibiotics should be carried out. This is unlikely to take place, as the number of the patients required will be too much and the recent guidelines have already recommended the prophylaxis for the patients considered to be at high risk⁶⁸.

Good oral hygiene is probably the most important factor in reducing risk of IE in susceptible individuals and access to high quality dental care should be facilitated once a patient is found to have cardiac anomaly putting him at higher risk of Endocarditis. He should be referred to a dentist to optimize the dental hygiene, Patients undergoing valve replacement, placement of aortic grafts or conduit should also be referred for dental assessment. The dental treatment preferably should be completed fifteen days ahead of planned cardiac surgical procedures in order to allow dental mucosal healing, All elective dental procedures should be delayed for at least three months after cardiac surgery⁶⁸.

The degree of oral inflammation and infection is proportional to the incidence and magnitude of bacteraemia^{69,70} Dental procedures which can lead to significant bacteraemia and those creating Medium and low risk of bacteraemia are shown in Table 3⁷¹⁻⁷⁶.

TABLE 3: MODIFIED FROM THERAPEUTIC GUIDELINES JUNE, 2006.

High-risk dental procedures	Medium-risk dental procedures	Low-risk dental procedures
Extraction Periodontal procedures including surgery and root planning Replanting avulsed teeth Other surgical procedures (e.g.) (implant placement, apicoectomy)	Periodontal probing Intraligamentary and intra-osseous local anaesthetic injection Supragingival calculus Removal/cleaning Rubber dam placement with clamps (where risk of damaging gingival) Restorative matrix/band strip placement Endodontics beyond the apical foramen Placement of orthodontic bands Placement of interdental wedges Subgingival placement of retraction cords, antibiotic fibers or antibiotic strips	Oral-examination Infiltration and block local anaesthetic injection Restorative dentistry Supragingival rubber dam Clamping and placement of rubber dam Intracanal endodontic procedures Removal of sutures Impressions and construction of dentures Orthodontic bracket placement and adjustment of fixed appliances Application of gels Intraoral radiographs supragingival plaque removal

Antibiotics prophylaxis is indicated to prevent endocarditis when a patient with known cardiac condition undergoes dental treatment. Dental procedures induce bacteraemia with bacterial species that often are typical causative microorganisms leading to endocarditis. Endocarditis carries high morbidity and mortality; therefore, antibiotics should be administered to susceptible patients before dental procedures to prevent endocarditis⁵¹. In experimental models antibiotics have been proven as a definite treatment to prevent endocarditis^{51,77,78}. On these grounds, prophylaxis against endocarditis is widely recommended^{45,51}.

The need for antibiotics for endocarditis prevention has been questioned repeatedly⁸⁰⁻⁸⁶. The less the

evidence there is, the more antibiotic we give. Three major studies^{82,86,87} and several outcomes analyses and commentaries^{80, 81, 84, 85} have presented substantial grounds to challenge the value of the invalidated practice of administering antibiotics before dental procedures to prevent endocarditis.

A Dutch study⁸² assessed 427 patients with endocarditis and found that 64% of the patients would have been candidates for prophylaxis based on previous cardiac conditions. This study further concluded that even if antibiotic prophylaxis was 100% effective and was provided to all patients who were at risk, small fraction (5.3%) would be potentially prevented.

TABLE 4 MODIFIED FROM CONCISE GUIDELINES OF BRITISH CARDIAC SOCIETY⁷⁹

Dental Procedures and Antibiotic prophylaxis for high-risk and low risk cases	
Prophylaxis Required	Prophylaxis not required
Periodontal probing	Dental examination
Sialography	Intra – oral radiographs
Polishing teeth with rubber cup	Extra – oral radiographs
Oral irrigation with water jet	Fissure sealants
Light scaling	Fluoride treatments
Deep scaling	Airpolishing
Scaling teeth with hand instrument	Infiltration local anaesthetic injections
Scaling with ultrasonic instrument	Nerve block local anaesthesia
Intraligamental local anaesthetic injections	Oral airway for GA
Comprehensive dental treatment under general anaesthesia and extraction and fillings	Nasal airway for GA
Rubber dam placement	Laryngeal mask airway for GA
Matrix band and wedge placement	Slow and fast drilling of teeth (without rubber dam)
Gingival retraction cord placement	Root canal instrumentation with the root canal
Root planning (similar to scaling)	Vital pulpotomy of primary molar
Antibiotic fibers or strips placed subgingivally	Pulpotomy of permanent tooth
Gingivectomy	Alginate impressions
Periodontal surgery	Placement of removable appliances
Root canal instrumentation beyond the apex	Band placement and cementation
Avulsed tooth reimplantation	Band removal
Non – vital pulpotomy of primary molar	Adjustment of fixed appliances
Tooth separation	Incision and drainage of an abscess without extraction
Expose or expose and bond tooth/teeth	Dental implants – transmucosal fixture
Extraction of single tooth	Suture removal
Extraction of multiple teeth	Removal of surgical packs
Incision and drainage of an abscess with extraction	Exfoliation of primary teeth
Mucoperiosteal flap to gain access to tooth or lesion	Tooth brushing
Dental implants (as mucoperiosteal flap)	Flossing
	Use of interdental wooden points

A more recent study⁸⁷ assessed 287 cases from Philadelphia area and concluded that there was no significant relationship between development of IE and dental procedures even in patients with valve disease. The statistical risk for endocarditis did not change regardless of whether antibiotics were used in dental treatment. Although this study confirmed that underlying heart disease is the major risk factor of IE. Only few cases of IE were prevented with the use of chemoprophylaxis even if antibiotics were 100% effective and given to 100% of the patients when indicated.

David Durack in a review article⁸⁸ said that time has come to scale back on prophylaxis against endocarditis before dental treatment. In the matrix of procedures related to predisposing conditions, prophylaxis should be downgraded to "not recommend" for most dental procedures except extractions and gingival surgery (including implant placement) and for most underlying cardiac conditions except prosthetic valves and previous endocarditis. When any one or more of these four high-risk factors is present, prophylaxis should follow the present American Heart Association (AHA) guidelines⁴⁵.

Mitral valve prolapse without mitral regurgitation is not included among the underlying conditions requiring routine prophylaxis because although a signifi-

cant number of cases of endocarditis do occur in patients with mitral valve prolapse, the denominator of susceptible persons is large and the risk encountered by an individual patient with mitral valve prolapse is lower than that for patients with prosthetic valves, previous endocarditis, or both⁵¹. Furthermore, the prognosis for cure of viridians streptococcal endocarditis in a patient with mitral valve prolapse is good¹²⁻¹⁶.

Although failure of Antibiotic Prophylaxis is not rare but failure to give prophylaxis is considered to be a malpractice. Despite all the challenges recommendations for IE prophylaxis are existing and should be incorporated into day to day dental practice.

Before recommending the prophylactic antibiotic, one must remember the common cardiac conditions which can pose risk of Infective Endocarditis. They have been divided into three sub-groups, High, moderate and low risk group according to Therapeutic guidelines revised in July 2006 (Table 5) Mitral valve prolapse with mitral regurgitation has been placed in high risk group by these guidelines which differ from the AHA⁴⁵ guidelines and British society of antimicrobial chemotherapy (BSAC) guidelines⁸⁹ in which mitral valve prolapse associated with mitral regurgitation is placed in medium risk group,

TABLE 5: MODIFIED FROM THERAPEUTIC GUIDELINES JUNE, 2006

High-risk conditions	Medium-risk conditions	Low-risk conditions
Prosthetic cardiac valves Bioprosthetic Homograft Previous infective endocarditis Complex cyanotic Congenital Heart Disease (transposition, tetralogy of Fallot) Surgically constructed Systemic-pulmonary shunts or conduits Mitral valve prolapse with clinically significant regurgitation Acquired valvular dysfunction (e.g. rheumatic heart disease) in indigenous patients	Acquired valvular dysfunction (e.g. rheumatic heart disease) in non-Indigenous patients Congenital cardiac malformations other than those defined as high-or-low-risk hypertrophic cardiomyopathy Significant valvular/haemodynamic dysfunction associated with septal defects	Isolated secundum Atrial septal defects Surgical repair of septal defects Previous coronary artery bypass grafts or stents Mitral valve prolapse without regurgitation Physiological, functional or innocent murmur Previous Kawasaki disease without valvular dysfunction Cardiac pacemakers Pulmonary stenosis Heart-lung transplants

The mortality in patients with Infective Endocarditis remains very high. It depends upon many factors, including the nature of causative microorganisms being highest for pseudomonas Aeruginosa (50%), followed by Staphylococcus Auerus (26 — 47%), streptococcus bovis and streptococcus viridians (4 — 16%) and also the host response. Immunosuppressed patient and infected with HIV have worse prognosis. Similarly, patients who get complications like Perivalvular and Myocardial abscess have worse outcome. The overall mortality rate of both native valve and prosthetic valve endocarditis remains around 20 — 25%. Relapse of the endocarditis can occur within 6 months. Relapse rate is usually around 2%. The treatment failure is another important factor, leading to high mortality particularly in patients with Staphylococcus Endocarditis ⁹⁰.

Over the past few decades, substantial improvements have been made in the diagnosis and management of Infective Endocarditis, Treatment requires multi disciplinary approach. Successful and safe pa

tients' management is accomplished appropriately by obtaining a detailed medical history and physical examination. The examination should be aimed at identifying the physical signs. Medical consultation is recommended if a dentist comes across with a patient who has the history suggestive of cardiac abnormality or who has physical signs suggestive of heart diseases.

In general, the trend has been to more specifically describe those conditions that pose significant risk for patients and to delineate low or negligible risk situations, As a result, antibiotic prophylaxis is now recommended for fewer conditions. These changes also reflect improvements in the understanding of these disease processes and changing the attitude toward the use of antibiotic. The most notable among these changes include reducing the oral dose of amoxicillin from 3 grams to 2 grams, recommending that the follow-up dose of antibiotic be discontinued, and replacing erythromycin with other antibiotics as alternatives to the penicillin. Dajani and colleagues⁴⁵ have repor-

TABLE 6: MODIFIED FROM; DAJANI AD, TAUBERT KA, WILSON W, ET AL, PREVENTION OF BACTERIAL ENDOCARDITIS, RECOMMENDATION BY THE AMERICAN HEART ASSOCIATION JADA 1997, 128; 1142-1151, THERAPEUTIC GUIDELINES JUNE, 2006.

Antibiotic Prophylactic Regimens for Certain Dental Procedures		
Situation	Antibiotic	Regimen
Standard prophylaxis	Amoxicillin	Adults: 2.0 grams; Children: 50 mg/kg orally one hr before procedure
	Ampicillin (oral treatment Not tolerated)	Adults: 2.0 g IM§ or IV§; Children: 50 mg/kg IM or IV within 30 min. before procedure
Allergic to Penicillin	Clindamycin	Adults: 600 mg; Children: 20 mg/kg orally 1 hr. before procedure
	Oral therapy not tolerated	Adults: 600 mg; Children 15 mg/kg IV 1 hr. before procedure
		Cephalaxin or cefadroxil
	Oral therapy not tolerated	Adults: 1.0 g; Children: 25 mg/kg IM or IV within 30 min. before procedure
		Azithromycin or clarithromycin

ted that 2 g of amoxicillin provides several hours of antibiotic coverage, Table 6 shows the new recommendations for prophylactic coverage for certain dental procedure

In conclusion, the patient must be instructed to report back if he suffers from any unexplained illness after dental procedure, Patients with physiological heart murmurs do not require prophylaxis. Self reported history of heart valve disease should not be the sole criterion, In cases of corrective surgery for a patient with patent ductus arteriosus, antibiotic coverage is only required for the initial 6 months after surgery. Sufficient data to support prophylactic antibiotic in cardiac transplant recipients is lacking. It is recommended to consult cardiologist if such patients attends dental clinic. It is worth noting that such patients have reduce immune response and will require meticulous care jointly by physician and dental care provider. Fixed acrylic orthodontic appliances often harbor high level of streptococcus viridians. These appliances should not be used in high risk patients. Removable appliances should be cleaned regularly, When several appointments are needed for invasive dental treatment, interval of 9 —14 days should be left to reduce the risk of overgrowth of organisms. The use of antibiotic prophylaxis during placement of dental implant is controversial. More knowledge is required to clarify the controversies.

Despite the appropriate Antibiotic Prophylaxis, Infective Endocarditis may still occur. The frequently updated guidelines for Chemoprophylaxis against IE are confusing and cumbersome, so the dentist is ultimately responsible to make decision on his or her clinical judgment to select patient who will benefit from prophylaxis. Considering that the incidence of endocarditis following most procedure is low; a reasonable approach should consider the degree to which the patient's underlying condition carries risk of endocarditis, apparent risk of bacteraemia with procedure, potential adverse effects of antibiotics used and cost effectiveness of recommended prophylactic regime. The AHA has removed Erythromycin from the current recommendations because of its complex pharmacokinetics and its side effects particularly the gastrointestinal tract disturbances. However the physicians and dentists who have successfully used this drug may elect to continue with same practice.

Prevention of IE does not mean that the emphasis should be on antibiotic prophylaxis only but more vigilance should be on the patient's dental care and systemic illnesses as a whole. Adequate and prompt treatment of infection responsible for bacteraemia or fungemia, removal of colonized intravascular devices, effective management of recurrent infections responsible for chronic bacteraemia is more important.

High risk patients, who had past history of Infective Endocarditis, history of valve replacement, or have undergone surgically constructed systemic or pulmonary shunts require special attention and supervised care jointly by physician and dentist. The most recent guidelines by British society of antimicrobial chemotherapy (BSAC) have recommended limiting the prophylaxis to only this high risk group. The debate over the relationship between dentistry and Infective Endocarditis will continue. More research particularly randomized clinical trials are required to clear the controversies, however the evidence is emerging that dental treatment is less likely to be the cause of IE than thought previously. Despite the fact that there is lack of evidence favoring antibiotics prophylaxis the existing recommendations remain unchanged and need of safe and wise incorporation of these guidelines in the dental practice is of utmost importance,

REFERENCES

- 1 Van der Meer JTM, Thompson J, Valkenburg HA. Michael MF: Epidemiology of bacterial endocarditis in the Netherlands. I. Patients characteristics. Arch Intern Med 152:1863, 1992.
- 2 Hogevik H. Olaison L, Andersson R, et al: Epidemiologic aspects of Infective endocarditis in urban population: a 5-year prospective study. Medicine (Baltimore) 74:324-339, 1995.
- 3 Hoen B, Alla F, Selton-Suty C, et al: Changing profile of Infective endocarditis: Results of a 1-year survey in France. JAMA 288:75, 2002.
- 4 Cabell CH, Jollis JG, Peterson GE, Corey GR, Anderson DJ, Sexton DJ, Woods CW, Reller LB, Ryan T, Fowler VG Jr. changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162: 90-94.
- 5 Hoen B, Alla T, Seton-Suty C, Beguinot I. Bouvet A, Briancon S, Casalta JP, Danchin N, Delehay F, Etienne J, Le Moing V, Lepret C, Mainardi JL, Ruimy R, Vandenesch F; Association pour l'Etude et la Prevention de l'Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis: results of a one-year survey in France. JAMA. 2002; 288:75-81.

- 6 Roder BL, Wandall DA, Frimodt-Moller N, Espersen F, Skinhoj P, Rosdahl VT. Clinical features of Staphylococcus aureus endocarditis. Arch Intern Med. 1999; 159: 462-469.
- 7 Miro JM del Rio A, Mestres CA: Infective endocarditis in intravenous drug abusers and HIV-1 infective patients. Infect Dis Clin North Am 16:273, 2002.
- 8 Stein A, Raoult D: Q fever endocarditis. Eur Heart J 16 (Suppl B):19, 1995.
- 9 Raoult D, Fournier PE, Drancourt M, et al: Diagnosis of 22 new cases of Bartonella endocarditis Ann Intern Med 125: 646, 1996.
- 10 Sande MA, Lee BL, Millis J, et al: Endocarditis in intravenous drug users. In Kaye D (ed): Infective Endocarditis. 2'd ed. New York, Raven Press, 1992, p 345.
- 11 Matthew J Addai T, Anand A, et al: Clinical features, site of involvement, bacteriologic findings, and outcome of infective endocarditis in intravenous users. Arch Intern Med 155:1641, 1995.
- 12 BonowRO, CarabelloB, deLeon AC jr et al. Guidelines for the management of patients with valvular heart disease:executive summary:a report of the American college of cardiology/ American heart association Task force on practice guidelines (committee on managements of patients with valvular heart disease) circulation1998;98:1949-84.
- 13 Zuppiroli A,Rinaldi M,Kramer-Fox R,Favilli S,Roman MJ, Devereux RB.Natural history of mitral valve prolapse.Am J Cardiol 1995;75:1028-32.
- 14 Arvay A,Lengyl M,incidence and risk factors of prosthetic valve endocarditis. Eur J cardiothorac surg 1988;2:340-6.
- 15 Calderwood SB, Swinski LA,Waternaux CM,Karchmer AW, Buckley MJ. Risk factors for he development of prosthetic valve endocarditis. Circulation 1985;72:31-7.
- 16 Ivert TS,Dismukes WE,Cobbs CG,Blackstone EH,Kirklin JW, Bergdahl LA. Prosthetic valve endocarditis. Circulation 1984;69:223-32.
- 17 Geraci JE Wilson WR symposium on infective edocarditis III: endocarditis due to gram-negative bacteria,Mayo clinic proc. 1982;57,145-148
- 18 Pierroti LC,Baddour LM,Fungal Endocarditis,1995-2000 chest. 2002;122;302-310
- 19 Ellis ME,A1-Abdely H,Sandridge A,Greer W,Ventura W,Fungal endocarditis evidence in the wold literature,1965-1995. infect.dis.200;32:50-62
- 20 Thomas F.Keys,MD,Infective Endocarditis, Cleveland clinic, July 2004.
- 21 Krachmer AW: Infections of prosthetic heart valves. In Waldvogel F, Bisno AL (eds): Infections Associated with Indwelling Medical Devices. Washington, DC, American Society for Microbiology, 2000 pp 145-172.
- 22 Livornese LL, Jr, Korzeniowski OM Pathogenesis of infective endocarditis, Infective endocarditis 2nd edition 1992, p19
- 23 Whitener C, Caputo GM, Weitekamp MR, Karchmer AW: Endocarditis due to coagulase-negative staphylococci: Micro-biologic, epidemiologic, and clinical considerations. Infect Clin Dis North Am 7:81, 1993.
- 24 Roder BM, Wandall DA, Frimodt-Moller N, et al: Clinical features of Staphylococcus aureus endocarditis. A 10-year experience in Denmark. Arch Intern Med 159:462, 1999.
- 25 Fowler Vg Jr, Sanders LL, Kong LK et al: Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 28:106, 1999.
- 26 Hessen MT, Abrutyn E: Gram-negative bacterial endocarditis. In Kaye D (ed): Infective Endocarditis 2nd ed. New York. Raven Press, 1992, p 251.
- 27 Brouqui P, Raoult D: Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 14:177, 2001.
- 28 Berbari EF, Cockerill FR III, Steckelberg J: Infective endocarditis due to unusual or fastidious microorganisms. Mayo Clin Proc 72:532, 1997.
- 29 Crawford MH,Durack DT, Clinical presentation of infective endocarditis, Cardiol clinic, 21;159,2003
- 30 Weinstein L, Schlesinger JJ Pathoanatomic, pathophysiological, and clinical correlation in Endocarditis, NEngl J Med, 291;1122,1974
- 31 Mansur AJ, Grinberg M,Lamos da Luz P, Bellotti G; The complication of infective endocarditis Archives of Inter Med 152;2428,1992.
- 32 Disalvo G, Habib G, Pergola V,Echocardiography predicts embolic events in infective endocarditis J American cool Cardiol 37;1077,2001
- 33 Von Reyn CF, Levy BS, Arbeit RD, Friedland G, Crum-packer CS. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med. 1981; 94: 505-518.
- 34 Durack DT, Lukes AS, Bright KD et al. New criteria for diagnosis of infective endocarditis: Utilization of specific echocardiographic findings. Am J Med. 1994;96: 200-209.
- 35 Li JS, Sexton DJ, Mick N, Proposed modification to the Duke criteria for the diagnosis of infective endocarditis Clin infect Dis 30;633,2000.
- 36 Bayer AS,Bolger AF,Taubert KA,Diagnosis and management of infective endocarditis and its complications Circulation98;2936,1998.
- 37 Bayer AS, LamK, Ginzton L, Norman DC, Chiu CY, Ward JI, Staphylococcus aureus bacteraemia, clinical, serological and echocardiographic finding in patients with and without endocarditisArch of intern med 1987,147; 457-462
- 38 Braunwalds text book of Cardiovascular medicine chapter 58 p 1643
- 39 Sochowski RA, Chan KL, Implications of negative results on monoplane transesophageal echo *study* in patients with suspected infective endocarditis, J Amer Coll Cardiol.
- 40 Baltch AL, Pressman HL, Schaffer C, et al, Bacteraemia in patients undergoing oral procedures Arch Inter Med, 1988;148;1984-1088.
- 41 Everett ED, Hirschmann JV. Transient bacteraemia and endocarditis prophylaxis. A review. Medicine 1977; 56: 61-77

- 42 Burket LW, Burn CG. Bacteraemias following dental extraction. Demonstration of source of bacteria by means of a non pathogen (*Serratia marcescens*). *J Dent Res* 1937; 16: 521-30.
- 43 Fiehn NE, Gutschik E, Larsen T, Bangsberg JM. *J Clin Microbiol* 1995; 33: 1399-1401 7.
- 44 Endocarditis Working Party of the British Society for Antimicrobial Chemotherapy. Recommendations for endocarditis prophylaxis. *J Antimicrob Chemother* 1993; 31: 437-
- 45 Dajani AS, Taubert KA, Wilson W, Bolger AF, Bayer A, Ferrieri P, Gewitz MH, Shulman ST, Nouri S, Newburger JW, Hutto C, Pallasch TJ, Gage TW, Levison ME, Peter G, Zuccaro G. Prevention of bacterial endocarditis. Recommendations by The American Heart Association. *J Am Med Assoc* 1997; 277: 1794-1801
- 46 Roberts G J, Holzel H, Sury MRJ, Simmons NA, Gardner P, Longhurst P. Dental bacteraemia in children. *Pediatr Cardiol* 1997; 18:
- 47 Risk factors for infective endocarditis, Strom et al, *Circulation* 2000;102;2842-2848
- 48 Van der Meer JT, van Wijk W, Thompson J, Vande Valkenburg HA, Michel MC. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis *Lancet* 1992;339: 135-9.
- 49 Cawson RA. Antibiotic prophylaxis for dental treatment. *BMJ* 1992;304:933-4.
- 50 Wehrmacher WH. Myths: endocarditis [editorial]. *Arch Intern Med* 1994;154:129-30.
- 51 Durack DT. Prevention of infective endocarditis. *N Engl J Med* 1995;332:38-42
- 52 Mealey BL. Influence of periodontal infections on systemic health. *Periodontol* 2000 1999;21:197-209
- 53 Slavkin HC. Does the mouth put the heart at risk? *J Am Dent Assoc* 1999;130:109-113.
- 54 Loesche W. Periodontal disease: Link to cardiovascular disease. *Compend Contin Educ Dent* 2000;21:463-466, 468, 470.
- 55 Joshipura KJ, Rimm EB, Douglass CW, Trichopoulos D, Ascherio A, Willett WC. Poor oral health and coronary heart disease. *J Dent Res* 1996;75:1631-1636.
- 56 Mattila KJ, Asikainen S, Wolf J, Jousimies-Somer H, Valtonen V, Nieminen M. Age, dental infections, and coronary heart disease. *J Dent Res* 2000;79:756-760.
- 57 Roberts GJ, Simmons NB, Langhurst P. Odontogenic bacteraemia and intraligamental analgesia. *Br Dent J*, 1992; 173:195.
- 58 Pallasch TJ. Antibiotic prophylaxis: Theory and reality. *Calif Dent Asso J* 1989;17:27-39
- 59 Rees TD. Periodontal considerations in patients with bone marrow or solid organ transplants. In: Rose LF, Genco RJ, Cohen DW, Mealey BL, eds. *Periodontal Medicine*. Toronto: Decker Inc.; 1999.
- 60 Kinane DF. Periodontal diseases' contribution to cardiovascular, An overview of potential mechanisms. *Ann Periodontol* 1998; 3:142-150.
- 61 Mealey BL. Periodontal implications: Medically compromised patients. *Ann Periodontol* 1996;1:256-321.
- 62 MacFarlane TW, Ferguson MM, Mulgrew CJ. Postextraction bacteraemia: Role of antiseptics and antibiotics. *Br Dent J* 1984;156:179-181.
- 63 Barco CT. Prevention of infective endocarditis: A review of the medical and dental literature. *J Peri-odontol* 1991;62: 510-523.
- 64 Bender IB, Naidorf IJ, Garvey GJ. Bacterial endocarditis: A consideration for physician and dentist. *J Am Dent Assoc* 1984;109:415-420.
- 65 Tzukert AA, Leviner E, Sela M. Prevention of infective endocarditis: Not by antibiotics alone. *Oral Surg Oral Med Oral Pathol* 1986;62:385-388.
- 66 Seymour RA, Lowry R, Whitworth JM et al. Infective endocarditis, dentistry and antibiotic prophylaxis; time for arethink? *Br Dent J* 2000;189:610-5.
- 67 Oliver R, Roberts GJ, Hooper L. Penicillins for the prophylaxis of bacterial endocarditis in dentistry. *Cochrane Database Syst Rev* 2006
- 68 Guidelines for the prevention of endocarditis, Report of the working party of British Society of Antimicrobial Chemotherapy, *J Antimicrobial Chemo*, 2006,57,1035-1042
- 69 Pallasch TJ, Slots J. Antibiotic prophylaxis and the medically compromised patient. *Periodontol* 2000 1996;10:107-38.
- 70 Bender IB, Naidorf IJ, Garvey GJ. Bacterial endocarditis: a consideration for physician and dentist. *J Am Dent Assoc* 1984;109:415-20.
- 71 Blanco-Carrion A. Bacterial endocarditis prophylaxis. *Med Oral Patol Oral Cir Bucal* 2004; 9: S37-51.
- 72 Baltch AL, Schaffer C, Hammer MC et al. Bacteraemia following dental cleaning in patients with and without penicillin prophylaxis. *Am Heart J* 1982; 104: 1335-9.
- 73 Ochsenfahrt C, Friedl R, Hannekum A et al. Endocarditis after nipple piercing in a patient with a bicuspid aortic valve. *Ann Thorac Surg* 2001; 7: 1365-6.
- 74 Finkelman JD, Gimenez M, Pietrangolo C et al. Endocarditis as a complication of a transjugular intrahepatic portosystemic stent-shunt. *Clin Infect Dis* 1996; 22: 385-6.
- 75 Park S, Montoya A, Moreno N et al. Infective aortic endocarditis after percutaneous balloon aortic valvuloplasty. *Ann Thorac Surg* 1993; 56: 1161-2.
- 76 Fervenza FC, Contreras GE, Garratt KN et al. *Staphylococcus lugdunensis* endocarditis: a complication of vasectomy? *Mayo Clin Proc* 1999; 74: 1227-30.
- 77 Moreillon P, Francioli P, Overholser D, Meylan P, Glauser MP. Mechanisms of successful amoxicillin prophylaxis of experimental endocarditis due to *Streptococcus intermedius*. *J Infect Dis*. 1986; 154:8017.
- 78 Malinverni R, Francioli PB, Glauser MP. Comparison of single and multiple doses of prophylactic antibiotics in experimental streptococcal endocarditis. *Circulation*. 1987; 76: 376-82.
- 79 Prophylaxis and treatment of infective endocarditis in adults, concise guidelines p 1-9.

- 80 Guntheroth WG. How important are dental procedures as a cause of infective endocarditis? *Am J Cardiol.* 1984; 54: 797-801.
- 81 Clemens JD, Ransohoff DF. A quantitative assessment of pre-dental antibiotic prophylaxis for patients with mitral-valve prolapse. *J Chronic Dis.* 1984; 37:531-44.
- 82 Van der Meer JT, Thompson J, Valkenburg HA, Michel MF. Epidemiology of bacterial endocarditis in The Netherlands. II. Antecedent procedures and use of prophylaxis. *Arch Intern Med.* 1992; 152:1869-73.
- 83 Wahl MJ. Myths of dental-induced endocarditis. *Arch Intern Med.* 1994; 154:137-44.
- 84 Bor DH, Himmelstein DU. Endocarditis prophylaxis for patients with mitral valve prolapse. A quantitative analysis. *Am J Med.* 1984; 76:711-7.
- 85 Pallasch TJ. A critical appraisal of antibiotic prophylaxis. *Int Dent J.* 1989; 39:183-96.
- 86 Van der Meer JT, Van Wijk W, Thompson J, Vandenbroucke JP, Valkenburg HA, Michel MF. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. *Lancet.* 1992; 339:1359.
87. Strom BL, Abrutyn E, Berlin JA, Kinman JL, Feldman RS, Stolley PD, et al. Dental and cardiac risk factors for infective endocarditis. A population-based, case—control study. *Ann Intern Med.* 1998; 129:761-9.
88. Antibiotics for Prevention of Endocarditis during Dentistry: Time To Scale Back? David T. Durack, MB, DPhil *Annals of internal medicine* 15 November 1998 Volume 129 Issue 101 Pages 829-831
89. Gould FK, Elliott TSJ, Foweraker J, et al. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2006;57:1035-1038
90. Hasbun R, Vikram HR, Barakat LA, Risk classification in mortality, *JAMA* 289;1933,2003.